Dynamics of entanglement in a one-dimensional Ising chain

The evolution of entanglement in a one-dimensional Ising chain is numerically studied under various initial conditions. We analyze two problems concerning the dynamics of the entanglement: (i) generation of the entanglement from the pseudopure separable state and (ii) transportation of the entanglement from one end of the chain to the other. The investigated model is a one-dimensional Ising spin-1/2 chain with nearest-neighbor interactions placed in an external magnetic field and irradiated by a weak resonant transverse field. The possibility of selective initialization of partially entangled states is considered. It was shown that, in spite of the use of a model with the direct interactions between the nearest neighbors, the entanglement between remote spins is generated.Comment: 19 pages, 7 figure

Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges

More than 40 nanomedicines are already in routine clinical use with a growing number following in preclinical and clinical development. The therapeutic objectives are often enhanced disease- specific targeting (with simultaneously reduced access to sites of toxicity) and, especially in the case of macromolecular biotech drugs, improving access to intracellular pharmacological target receptors. Successful navigation of the endocytic pathways is usually a prerequisite to achieve these goals. Thus a comprehensive understanding of endocytosis and intracellular trafficking pathways in both the target and bystander normal cell type(s) is essential to enable optimal nanomedicine design. It is becoming evident that endocytic pathways can become disregulated in disease and this, together with the potential changes induced during exposure to the nanocarrier itself, has the potential to significantly impact nanomedicine performance in terms of safety and efficacy. Here we overview the endomembrane trafficking pathways, discuss the methods used to determine and quantitate the intracellular fate of nanomedicines, and review the current status of lysosomotropic and endosomotropic delivery. Based on the lessons learned during more than 3 decades of clinical development, the need to use endocytosis-relevant clinical biomarkers to better select those patients most likely to benefit from nanomedicine therapy is also discussed